1. Introduction {#s0005}
===============

Posterior cortical atrophy (PCA) is characterised by progressive impairment of visuospatial and visuoperceptual function that is not attributable to ocular disease ([@bb0190]; [@bb0255]). Impaired object and space perception is prominent, often accompanied by other features of posterior cortical dysfunction. The most common underlying cause is Alzheimer\'s pathology ([@bb0220]), although in a minority of cases alternative aetiologies, including corticobasal degeneration, dementia with Lewy bodies and prion disease, are implicated ([@bb0075]).

Much research on PCA has concentrated on defining the visuospatial deficits ([@bb0070]). Diagnostic criteria emphasise that episodic memory is relatively spared in the early stages ([@bb0190]; [@bb0195]). However, there is accumulating evidence of memory dysfunction in PCA([@bb0190]; [@bb0050]), and our work has shown that encoding and retrieval of new verbal information is significantly impaired in PCA patients compared to controls at initial presentation ([@bb0005]). Recently published consensus criteria also report that some PCA patients commonly report prominent memory disturbances at clinical presentation ([@bb0075]). Since memory impairment could be amongst the presenting features in PCA, there is a need for better understanding of the neurocognitive mechanisms underlying this impairment, mechanisms which have to date remained entirely unexplored. Compared with tAD, voxel-based morphometry (VBM) studies in PCA show relatively minimal involvement of classically implicated memory circuitry i.e. the medial temporal lobes (MTL) ([@bb0145]; [@bb0160]; [@bb0280]). Instead, PCA patients show a characteristic pattern of atrophy in parieto-occipital and temporo-occipital cortices compared with controls, with significant grey matter reductions predominantly in the right superior parietal lobe ([@bb0160]). Brain perfusion studies show bilateral and symmetrical hypoperfusion of the posterior cortex, with the most marked decrease found in the inferior parietal cortex ([@bb0145]).

Memory is not a cognitive function typically credited to the lateral parietal regions. Classic discourses describing the function of the parietal lobe make little mention of memory processes (e.g., ([@bb0065]; [@bb0175])). Recent investigation, however, suggests that the lateral parietal cortex may play an integrative role in episodic memory that has been largely underappreciated. Episodic memory tasks consistently show greater lateral parietal activation for encoding and retrieval of items, although more commonly for the latter process ([@bb0080]; [@bb0140]; [@bb0265]), and lesion studies of patients with focal parietal damage provide further supporting evidence ([@bb0025]; [@bb0235]). Accordingly, given the relative sparing of the MTL in PCA, we hypothesize that memory impairment may be subserved by regions of the parietal lobe, and in particular, regions of the lateral parietal lobe that appear to be most severely compromised. This is in direct contrast to neural correlates of word list learning in AD. Using the Rey auditory verbal learning task (RAVLT), a widely used verbal episodic list learning task to quantify memory impairment in AD and preclinical AD, studies have shown consistent atrophy of medial temporal ([@bb0015]; [@bb0290]) and medial parietal regions ([@bb0030]) across imaging modalities.

The aim of this study was to characterise the behavioural and neuroanatomical profile of memory impairment in PCA. Specifically, we predicted that PCA patients would not differ from AD patient controls in free recall measures of new learning but that PCA patients would benefit more from assessment of memory using recognition memory test formats, showing normal performance, given relative sparing of the MTL. Anatomically, we hypothesised that impairment on word list learning would correlate with sites of early and typical dysfunction in the lateral parietal regions in PCA, rather than classic memory structures of the MTL.

2. Material and methods {#s0010}
=======================

2.1. Participants {#s0015}
-----------------

18 PCA patients were recruited through the Oxford Cognitive Disorders Clinic, Oxford, UK. Diagnosis was established by a senior behavioural neurologist (CRB, ST or MH) and neuropsychologists (IB and SA). All patients fulfilled consensus criteria for PCA ([@bb0255]; [@bb0075]), based upon clinical assessment, brain imaging and detailed neuropsychological assessment. Clinical magnetic resonance imaging (MRI) confirmed focal atrophy in the occipital and parietal lobes.

Three controls groups were used for comparison with the PCA patients. The first group (HC1) consisted of 21 healthy controls, and was used to analyse neuropsychological test performance in the PCA patients. These participants had no objective cognitive impairment (scored \>88 on the Addenbrooke\'s Cognitive Examination-Revised ([@bb0200])), and no prior history of psychiatric illness, significant head injury, or cerebrovascular disease, and were not prescribed any medication known to affect cognition.

The second group (tAD patient controls) consisted of 15 tAD patients, recruited from the dementia research clinic in Norwich, UK, as a disease control group for neuropsychological data analysis. tAD controls fulfilled consensus criteria for Alzheimer\'s disease ([@bb0180]; [@bb0185]), based upon clinical assessment, detailed neuropsychological assessment, and structural brain imaging. tAD patients showed marked impairment in episodic memory, with relatively preserved behaviour and personality, and characteristic bilateral medial temporal, with other more general atrophy.

PCA patients, HC1 and tAD control groups were matched for age, years of education and gender distribution ([Table 1](#t0005){ref-type="table"}). PCA and tAD controls were matched for symptom duration, i.e. time since the first symptom was noticed. PCA patients did not demonstrate evidence of depressed mood or elevated stress levels, but did show significantly raised anxiety levels compared to controls. However, the group average (3.4) was still well within the normal range (0--7) on the Depression, Anxiety Stress Scale (DASS).Table 1Demographic and clinical characteristics of control and patient groups. Standard deviation given in brackets. Total scores achievable on neuropsychological tests, where applicable, in brackets in right column. Values in bold indicate significant group differences.Table 1HC1HC2PCAtADHC1 × PCAHC1 × tADPCA × tADHC1 × HC2DemographicsN21451815------Age (yrs)63.4 (6.1)64.4 (7.2)64.9 (6.8)68.6 (9.7)0.8980.1260.4110.577Education (yrs)14.4 (2.1)14.2 (3.0)13.6 (2.0)12.6 (6.5)0.8210.4130.8240.751Gender (m:f)9:1225:20\#';lmn 9:98:70.6560.5350.8490.336Symptom duration (yrs)--/. M,./3.8 (1.9)3.0 (0.8)----0.130DASS[1](#tf0005){ref-type="table-fn"} depression scale (normal range 0--9)2.1 (2.5)5.5 (9.3)--0.119----DASS anxiety scale (normal range 0--7)1.0 (2.1)3.4 (3.1)--**0.019**----DASS stress scale (normal range 0--14)4.0 (4.5)5.6 (5.0)--0.318----Background neuropsychological profileACE III Total (100)96.0 (4.3)55.4 (15.7)66.9 (22.1)**0.0000.000**0.092ACE III Attention ([@bb0235])17.1 (1.5)10.9 (3.6)12.2 (4.9)**0.0000.000**0.621ACE III Memory ([@bb0295])24.7 (2.1)14.9 (5.2)12.6 (6.4)**0.0000.000**0.405ACE III Fluency ([@bb0080])12.7 (1.5)7.9 (4.2)8.1 (3.6)**0.0000.000**0.995ACE III Language ([@bb0295])25.7 (0.96)18.4 (6.4)21.7 (5.9)**0.000**0.0550.153ACE III Visuospatial function ([@bb0265])15.7 (0.72)3.8 (3.8)12.3 (3.4)**0.0000.0020.000***Visuospatial function*VOSP dot counting[1](#tf0005){ref-type="table-fn"} ([@bb0160])10.0 (0)3.9 (3.7)--**0.000**----VOSP position discrimination[1](#tf0005){ref-type="table-fn"} ([@bb0290])19.6 (1.1)13.5 (3.8)--**0.000**----VOSP cube analysis[1](#tf0005){ref-type="table-fn"} ([@bb0160])9.5 (1.2)1.8 (2.3)--**0.000**----Rey-Osterrieth complex figure copy[1](#tf0005){ref-type="table-fn"} ([@bb0235])17.6 (0.74)1.8 (3.1)--**0.000**----*Visual imagery*Spatial relations: categorical ([@bb0065])11.5 (0.93)8.4 (2.3)--**0.000**----Spatial relations: metric ([@bb0065])11.0 (0.67)7.9 (2.5)--**0.000**----Spatial relations: total ([@bb0185])22.4 (1.2)15.8 (4.0)--**0.000**----Animal imagery ([@bb0290])18.0 (1.0)15.4 (2.3)--**0.000**----Letter imagery ([@bb0290])19.3 (0.85)15.8 (3.4)--**0.000**----*Language*Pyramids and Palm Trees[1](#tf0005){ref-type="table-fn"} ([@bb0040])51.6 (0.68)46.6 (3.0)--**0.001**----Category fluency[1](#tf0005){ref-type="table-fn"}21.2 (3.8)9.4 (6.6)--**0.000**----FAS[1](#tf0005){ref-type="table-fn"}46.7 (12.9)32.5 (18.4)--**0.008**----RAVLTTotal learning across 5 trials (75)49.7 (9.0)29.5 (11.7)24.2 (13.5)**0.0000.000**0.343Immediate recall ([@bb0140])10.3 (2.9)5.1 (3.3)2.9 (2.2)**0.0000.0000.040**Delayed recall ([@bb0140])10.2 (3.2)4.3 (4.0)2.7 (2.4)**0.0000.000**0.229Recognition hits ([@bb0140])13.9 (1.6)13.1 (2.2)10.1 (4.5)0.349**0.0010.030**Recognition false positives ([@bb0205])2.0 (2.8)9.5 (7.6)4.4 (5.1)**0.001**0.2220.077Recognition memory index ([@bb0140])11.8 (3.7)3.6 (8.1)5.7 (5.3)**0.0010.001**0.464[^1][^2]

A third control group (HC2) consisted of a further 32 healthy participants, and was used solely for analysis of the PCA neuroimaging data. These controls were recruited from the Oxford Project to Investigate Memory and Ageing and the Memory and Amnesia Project, University of Oxford, UK (cohorts described fully in ([@bb0170]; [@bb0295])). PCA patients and HC2 controls were matched for age (HC2: mean = 69.7 years, SD = 7.4; PCA: mean = 63.8 years, SD = 6.9; p \> .05), education (HC2: mean = 14.5 years, SD = 3.5; PCA: mean = 13.7 years, SD = 1.9; p \> .05), and gender distribution (HC2: 19 males, 13 females; PCA: 6 males, 7 females). HC1 and HC2 were also matched on age, education and gender (p \> .05).

The study was approved by the National Research Ethics Service South Central - Hampshire B and Oxford C. All participants provided written informed consent in accordance with the Declaration of Helsinki.

2.2. Background neuropsychological tests {#s0020}
----------------------------------------

Standardised neuropsychological tests were administered to evaluate patient and control participant function in four domains:(i)*Global cognition*: Addenbrooke\'s Cognitive Examination-III ([@bb0135]).(ii)*Visuospatial function*: Dot counting, position discrimination and cube analysis from the Visual Object and Space Perception (VOSP; ([@bb0270]) and the Rey-Osterrieth Complex fig. (29).(iii)*Visual imagery*: Spatial Relations Test (adapted from ([@bb0150]; [@bb0215])), Letter Shape Test ([@bb0090]) and Tail Judgement Test ([@bb0095]).(iv)*Language*: Oral Pyramids and Palm Trees (PPT; ([@bb0130])), category fluency ([@bb0205]) and FAS letter fluency ([@bb0020]).

2.3. Memory assessment {#s0025}
----------------------

### 2.3.1. Subjective memory questionnaires {#s0030}

PCA patients\' perspectives of their memory function were assessed using the Everyday Memory Questionnaire (EMQ; ([@bb0250])) and carer perspectives were assessed using the Cambridge Behavioural Inventory-Revised (CBI-R; ([@bb0275])). Both patients and carers were instructed to answer questions with regards to memory and thinking and not poor visual functioning. For example, on the EMQ the last question asks how frequently the individual fails to recognise a close friend or relative -- the results ([Table 2](#t0010){ref-type="table"}) show that the majority of patients (93%) do not experience this problem in terms of memory loss, whereas if answered in terms of visual and perceptual symptoms in PCA, a higher proportion of patients would be expected to endorse this symptom. In both questionnaires, Likert scales were collapsed to provide a rating for symptoms experienced at three frequencies: Never, Frequent and Daily. Specifically, the CBI-R scales was collapsed as follows: "Never" = Never category; "a few times per month" and "a few times per week" = Frequent category; "daily" and "constantly" = Daily category. The EMQ scales was collapsed as follows: "not at all" = Never category; "about once in the last 3 months", "about once a month" and "about once a week" = Frequent category; "about once a day" and "more than once a day" = Daily category.Table 2Frequency of memory complaints observed by carers or expressed by PCA patients (at average symptom duration of 3.8 years). Symptoms highlighted in bold denote those that were endorsed by \>75% of the patient or carer group as occurring frequently or daily.Table 2Carer observation (N = 16)\
*(from the Cambridge Behavioural Inventory-Revised;*[@bb0275]*)*Frequency of complaint (%)NeverFrequentDailyNo answerPoor day-to-day memory37.51937.56Asks the same questions over and over again5625190**Loses/misplaces things**6**4444**6**Forgets the names of familiar people**12.5**7512.5**0**Forgets the names of objects and things**6**62.525**6Poor concentration when reading/watching television12.53137.519Forgets what day it is2562.512.50**Becomes confused/muddled in unusual surroundings**6**4444**6PCA patients\' subjective complaints (N = 14)\
*(from the Everyday Memory Questionnaire; Sunderland* et al. *1983,*[@bb0250]*)***Forget where you put something**0**2264**14Fail to recognise places that you are told you have been to often before642277Fails to remember a change in your daily routine365707**Have to go back to check whether you had done something you meant to do**7**4336**14**Forget that you were told something yesterday/few days ago**14**6422**0Let yourself ramble on to speak about unimportant/irrelevant things574300**Have difficulty picking up a new skill**14**4336**7**Find that a word is "on the tip of your tongue"**0**3664**0Forget important details of what you did/forget what happened to you the day before504307Forget important details about yourself792100When talking to someone, forget what you had just said2950147When reading a newspaper/magazine, being unable to follow the thread of the story/lose track of what it was about36292114Forget to tell somebody something important712900**Get the details of what somebody has told you mixed up/confused**14**7214**0**Forget people\'s names**14**3650**0Get lost/turn in the wrong direction on a journey/walk/in a building you have only been to once/twice before14501422Repeat to someone what you have told them/ask the same question twice642970Fail to recognise a close relative93007

### 2.3.2. RAVLT {#s0035}

The RAVLT ([@bb0230]) was used to measure objective memory performance. This well-validated instrument has been extensively employed to evaluate verbal episodic memory performance in various dementia syndromes (e.g. AD: ([@bb0015]; [@bb0290]; [@bb0030]); FTD: ([@bb0125]); PCA: ([@bb0050])). A list of 15 unrelated words is read out to the participant five times, each time followed by free recall, in order to allow encoding of the word list. This is followed by an interference list of 15 new words. The original word list is then recalled immediately and at a delayed interval of 30 min. Recognition memory is assessed by presenting the participants with 50 words, consisting of 15 target words (i.e. the original word list) and 35 new words. If participants recognise a learned word, they respond "yes" (correct hit) and "no" to reject a new word. If participants incorrectly respond "yes" to a new word, it is scored as a false positive. A recognition memory index was calculated (hits - false positives) ([@bb0165]; [@bb0120]) to describe recognition ability taking into account response bias. Values closer to the maximum 15 denote better recognition memory.

2.4. Structural neuroimaging {#s0040}
----------------------------

Image acquisition was conducted on a Siemens 3 T Trio system using a 32-channel head coil at the University of Oxford Centre for Clinical Magnetic Resonance Research. High resolution, 3D T1-weighted images were acquired using a Magnetization Prepared Rapid Gradient Echo (MPRAGE) sequence (echo time = 4.7 ms, repetition time = 2040 ms, 8° flip angle, field of view = 192 mm, voxel size = 1 × 1 × 1 mm). Scans from 5 PCA patients were removed due to artifacts as a result of patient motion in the scanner. Structural data were analysed with an optimised protocol of the FSL-Voxel Based Morphometry (VBM) processing stream (see ([@bb0085])). In brief, images were brain extracted using the brain extraction tool (BET) ([@bb0240]) prior to tissue segmentation using the FMRIB Automatic Segmentation Tool (FAST). Images were non-linearly registered to standard space and an average study-specific template was created. All images were then non-linearly aligned to the study-specific template and modulated for correction of local field expansion or contraction by dividing the Jacobian of the warp field. Modulated images were then smoothed with an isotropic kernel with a sigma of 3 mm. Finally, voxel-wise statistics were employed using a general linear model with non-parametric permutation testing ([@bb0285]) and 5000 permutations per contrast.

### 2.4.1. Whole brain VBM analysis {#s0045}

To investigate differences in cortical grey-matter between PCA patients and HC2, regression models were applied with separate directional contrasts (i.e. *t*-tests). Results were defined as significant at p \< 0.001 corrected for multiple comparisons using the Threshold-Free Cluster Enhancement (TFCE) approach ([@bb0245]) carried out in Randomise with 5000 permutations per contrast.

### 2.4.2. Region of interest analyses {#s0050}

Analysis of the anatomical correlates of RAVLT metrics in PCA patients was restricted to the parietal region, based on the hypothesis that atrophy in this region constitutes the characteristic cortical signature of PCA and is therefore most likely to underpin memory deficits in PCA. A control region mask of the MTL was used to determine the specificity of parietal effects, since this is the region most commonly associated with memory dysfunction in other forms of dementia. Binary masks of the bilateral parietal lobes (including the supramarginal gyrus, precuneus cortex, angular gyrus, postcentral gyrus and superior parietal lobule) and bilateral MTL were taken from the Harvard-Oxford cortical structural atlas. Correlational analyses were conducted between grey matter density within these masks and performance on total learning across RAVLT trials, immediate recall, delayed recall, correct recognition and recognition sensitivity index, with correction for multiple comparisons using the TFCE approach in Randomise with 5000 permutations per contrast and significance defined as p \< 0.05. Age and gender were included as covariates in all analyses.

2.5. Statistical analyses {#s0055}
-------------------------

Demographic, clinical, and cognitive characteristics were explored using one-way analysis of variance with Sidak post hoc tests or independent samples t-tests, and Chi-squared tests for gender differences. RAVLT metrics were explored using Kruskal-Wallis nonparametric tests, with Mann-Whitney tests for pairwise comparisons. Spearman\'s rank correlation coefficient was used to explore relationships between RAVLT metrics and clinical variables. Two-tailed tests were conducted with alpha level set at 0.05, with Bonferroni correction applied for multiple comparisons.

3. Results {#s0060}
==========

3.1. Background neuropsychological assessment {#s0065}
---------------------------------------------

PCA patients were impaired on all visuospatial and visual imagery tests compared to HC1, in keeping with the clinical phenotype of this syndrome, with some decline in language also ([Table 1](#t0005){ref-type="table"}). Both PCA and tAD patients were impaired on the ACE-III compared to HC1, but there was no significant difference between patient groups.

3.2. Memory assessment {#s0070}
----------------------

### 3.2.1. Subjective memory questionnaires {#s0075}

The most common observations endorsed by carers (those observed by \>75% of carers as occurring frequently or daily) referred to symptoms related to memory retrieval and spatial memory. The most common subjective experiences of memory loss (those endorsed by \>75% of PCA patients) also pertained to memory retrieval, as well as task monitoring and memory for everyday activities ([Table 2](#t0010){ref-type="table"}).

### 3.2.2. RAVLT {#s0080}

Both PCA and tAD patients learnt significantly fewer words across trials compared to HC1, and there was no significant difference between patient groups ([Table 1](#t0005){ref-type="table"}). Both patient groups were impaired compared to HC1 on immediate recall, but PCA patients recalled significantly more than tAD patients. To further explore encoding, rate of learning was computed (calculated as Trial 5 recall - Trial 1 recall; ([@bb0110])). Although both PCA and tAD groups showed significantly reduced rate of learning compared to HC1 (PCA: p = .022; tAD: p = .040), PCA patients showed significantly more rapid learning than tAD patients (p = .040) ([Fig. 1](#f0005){ref-type="fig"}).Fig. 1Rate of learning (Trial 5 -- Trial 1) across groups. Error bars represent standard error of the mean. (\*p \< .05).Fig. 1

At retrieval, both patient groups were impaired compared to HC1 on delayed recall, and there was no difference between patient groups. Examining recognition, PCA patients were comparable to HC1 in correct identification of previously learned words (recognition hits), while the tAD group was impaired compared to HC1 and PCA patients. Conversely, PCA patients produced significantly more false positives compared to HC1, while the tAD group showed no difference compared to HC1, although there was no significant difference between the patient groups. The recognition memory index revealed that, once the number of false positives was accounted for, both PCA and tAD groups were impaired compared to HC1, and the performance of both patient groups was comparable.

3.3. Other clinical considerations {#s0085}
----------------------------------

Mood, symptom duration and impaired visual imagery were explored for their potential influence on poor memory performance in PCA.

### 3.3.1. Mood {#s0090}

There were no significant correlations between DASS stress, anxiety or depression measures with any of the RAVLT metrics (all p values \> .05).

### 3.3.2. Symptom duration {#s0095}

To explore whether the memory profile in PCA was being driven by patients with a longer symptom duration who may have accumulated more widespread cognitive symptoms, PCA patients were divided into two subgroups based on median length of symptom duration (median = 3.3 years), replicating the method used by Kas et al. ([@bb0145]): (i) a short symptom duration group defined as having less than or equal to three years symptom duration (n = 9); and (ii) a long symptom duration defined as having greater than three years symptom duration (n = 9). There were no significant differences between these groups on any of the RAVLT metrics (all p values \> .05). Supplementary analysis using symptom duration as a continuous variable revealed no significant correlations with the RAVLT.

### 3.3.3. Visual imagery {#s0100}

Poor visual imagery in PCA patients may impact the encoding process, based on evidence that visual strategies and mental imagery are commonly used to encode words presented in the auditory modality ([@bb0105]). There were no significant correlations between visual imagery tasks and RAVLT metrics.

3.4. Structural neuroimaging {#s0105}
----------------------------

### 3.4.1. Whole brain analyses {#s0110}

VBM analysis revealed significant decreases in grey matter density in PCA patients relative to HC2 ([Fig. 2](#f0010){ref-type="fig"}). PCA patients showed characteristic pronounced changes, largely bilateral, in the lateral occipital cortex, and in lateral and medial parietal regions, including the parietal lobule, angular gyrus, the supramarginal gyrus, precuneus and posterior cingulate. Medial temporal regions were largely spared except for grey matter density reduction in bilateral posterior parahippocampal gyrus and posterior hippocampus ([Table 3](#t0015){ref-type="table"}).Fig. 2Voxel based morphometry maps displaying reduced grey matter density in HC2 \> PCA. The comparison was significant at p \< 0.001 FWE corrected using TFCE method. Colour bars indicates T-values of statistically significant voxels.Fig. 2Table 3Results from voxel-based morphometry analyses. All clusters were significant at p \< 0.001 family-wise error corrected using threshold-free cluster enhancement method.Table 3ContrastRegionsCluster sizeCoordinatesT valuePCA \< HC2*Left:*\
paracingulate cortex, paracingulate gyrus\
*Right:*\
middle frontal gyrus\
*Bilateral:*\
superior parietal lobule, precentral gyrus, supramarginal gyrus, postcentral gyrus, posterior cingulate, angular gyrus, parietal operculum cortex, Heshl\'s gyrus, insular cortex, thalamus, superior temporal gyrus, middle temporal gyrus, inferior temporal gyrus, posterior parahippocampal gyrus, posterior hippocampus, putamen, caudate, precuneus, lingual gyrus, occipital fusiform gyrus, lateral occipital cortex, temporal fusiform gyrus, brain stem98,16656, −30, −47.86[^3]

### 3.4.2. Region of interest analyses {#s0115}

Analyses within the parietal lobe mask revealed a significant correlation between total learning across trials and grey matter density in the right supramarginal gyrus, right angular gyrus and left postcentral gyrus. The left post central gyrus also significantly correlated with immediate and delayed recall, correct recognition ([Fig. 3](#f0015){ref-type="fig"}). No correlations were detected between grey matter density within the parietal mask and the recognition memory index. No correlations with RAVLT metrics were detected within the MTL mask.Fig. 3Voxel based morphometry maps displaying correlation between reduced grey matter density in A = right supramarginal gyrus, right angular gyrus and left postcentral gyrus with total learning across trials; B = left postcentral gyrus with immediate recall; C = left postcentral gyrus with delayed recall and D = left postcentral gyrus with correct recognition in the PCA patients. Findings were significant at p \< 0.01 FWE corrected using TFCE method (p values by colour bar).Fig. 3

4. Discussion {#s0120}
=============

This study provides novel evidence that, contra to traditional understanding, PCA is associated with early verbal memory impairment. Moreover, the degree of memory impairment correlates with atrophy in the lateral parietal cortex rather than regions typically associated with memory impairment, such as the MTL in tAD.

Compared with healthy controls, PCA patients were impaired at learning, immediate recall and delayed recall of the RAVLT word list. Nevertheless, PCA patients performed better than tAD patients on measures of learning rate and immediate recall, although their delayed recall was not significantly different. This overall impairment of verbal recall in PCA is in line with the subjective complaints of patients, and with our previous, retrospective study ([@bb0005]). Importantly, the results could not be explained as a function of disease progression or mood disorder. However, whilst we expected to see a relative sparing of recognition memory in PCA, this was not observed. Although PCA patients scored as many 'hits' as healthy controls, this was due to a response bias indicated by their greater number of 'false positive' responses. The reason for this response bias is unclear. A recent study suggests disinhibition may play a role, i.e. patients are unable to constrain endorsement of recognition items ([@bb0100]), although on the CBI-R, disinhibition did not emerge as a prevalent feature in PCA. An alternative possibility is that PCA patients have reduced confidence in their memory, akin to that observed in patients with parietal lesions ([@bb0235]), leading to a liberal response bias. Further studies are needed to explain this observation.

Investigating the neural substrate of the verbal memory deficit in PCA, we found that atrophy in lateral parietal regions correlated with both encoding and retrieval. Specifically, grey matter density in the right supramarginal gyrus, right angular gyrus and left postcentral gyrus correlated with total learning across trials, and the left postcentral gyrus with immediate recall, delayed recall and correct recognition. No correlations were identified between memory performance and MTL atrophy. This is strikingly different from extensive previous research in tAD, where learning and retrieval impairments have consistently been attributed to pathology in the hippocampus and surrounding cortex (e.g. ([@bb0015]; [@bb0290]; [@bb0030])).

Two possible explanations for the observed neuroanatomical profile may be considered. First, the supramarginal gyrus has been associated with the phonological loop ([@bb0010]), which supports auditory-verbal working memory ([@bb0035]). Accordingly, supramarginal gyrus atrophy in PCA may disrupt working memory processes essential in a verbal memory task. However, such processes are likely to be most critical to successful encoding of verbal information and therefore to learning of the initial trials on the RAVLT. For example, in tAD patients, Wolk and Dickerson ([@bb0290]) found that reduced cortical thickness in the supramarginal gyrus correlated with learning on the initial trial of the RAVLT, while MTL structures correlated with total learning and delayed recall. In contrast, our results demonstrate that the supramarginal gyrus was associated with total learning and delayed recall in PCA patients, suggesting that impaired auditory-working memory is unlikely to be the primary deficit underpinning the memory impairment.

A second and more compelling possibility is that the lateral parietal correlates of memory in PCA reflect the hitherto under-recognised significance of these regions in episodic memory. Classic theories of memory would hypothesize that, because MTL involvement is not an early feature of PCA, patients should have relatively intact long-term declarative memory. However, an increasing number of fMRI (e.g. ([@bb0040]) and lesion (e.g. ([@bb0080]) studies have demonstrated a role for bilateral parietal cortex in both the encoding and retrieval of memories. The parietal cortex is also firmly linked with attentional processing and a rich body of neuropsychological, neurophysiological and neuroimaging literature shows anatomical co-localization of memory and attention processes in the lateral parietal cortex (see ([@bb0140]; [@bb0265]) for reviews), functionally dissociated along a dorsal (superior parietal lobe) and ventral (inferior parietal lobe, specifically the supramarginal gyrus) axis. Dorsal parietal mechanisms are proposed to direct attention to information that is relevant to the goal (top-down attention), enhancing cortical representation of the information being attended to and thus increasing the likelihood of later remembering. Ventral parietal mechanisms, by contrast, are proposed to be active when attention is captured by salient information (bottom-up attention), weakening later recall when attention is captured by information irrelevant to the task ([@bb0045]; [@bb0055]). The post central gyrus is frequently reported as part of the functional anatomy of attention and more specifically as part of the frontoparietal cortical network for directing attention ([@bb0060]). This may explain the correlation of the postcentral gyrus with several metrics from the RAVLT, and suggests a critical role for attention in episodic memory. Accordingly, we propose that memory impairment in PCA may be driven by the primary pathology in the parietal cortex, specifically affecting the attentional networks underlying memory processes.

Our results have important clinical implications. Memory is impaired early in the course of PCA, alongside the initial, defining visuo-perceptual impairments. As such memory assessments may aid accurate and early diagnosis of PCA, potentially within an optimal therapeutic window. Moreover, memory assessment may have particular utility in disease monitoring, since PCA patients typically perform at, or close to, floor on visual tasks even in the early stages of disease. If the attentional basis of memory impairment in PCA is borne out by future studies, everyday memory performance may be enhanced by implementing organisational or categorical cues at the time of encoding and by minimising attentional demands, directing attention and supporting retrieval (e.g. ([@bb0115])). Finally, the efficacy of pharmaceutical intervention for memory impairment in PCA should be explored. Research in tAD shows that deficits in shifting attention have been linked to reduced cholinergic innervation associated with hypometabolism of the posterior parietal cortex ([@bb0210]), and that administration of acetylcholinesterase inhibitors improves attention ([@bb0155]).

Our study has some limitations, which could be addressed by future research in order to investigate further the nature of memory impairment in PCA. First, visual imagery tests were not administered to the tAD group, and thus we were not able to explore differences between patient groups in visual imagery performance and its potential impact upon memory. Additional tests of attention and working memory could also be employed to understand more completely the contribution of these systems to memory impairment in PCA. Second, whilst the RAVLT has been used extensively to explore memory impairment in dementia ([@bb0015]; [@bb0290]; [@bb0030]) components of memory (i.e. encoding, recall and recognition) could be more systematically studied using free and cued memory tests (e.g. ([@bb0260])) that control encoding and retrieval of the material to be learnt.

5. Conclusions {#s0125}
==============

In summary, the results of this study provide the first description of the neural correlates of memory impairment in PCA, and strongly suggest that the deficits are underpinned by damage within parietal rather than medial temporal lobe networks. Future work is warranted to explore the relationship between attention and memory in PCA.
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[^1]: Abbreviations: ACE III Addenbrooke\'s Cognitive Examination; DASS Depression anxiety stress scale; HC1 Healthy controls group 1 (controls for behavioural data); HC2 Healthy control group 2 (controls for imaging data); PCA Posterior cortical atrophy; tAD typical Alzheimer\'s disease; VOSP Visual object and space perception; RAVLT Rey auditory verbal learning task.

[^2]: Missing data: Data in PCA patients was missing for some tests due to the test being ended on the patients\' request: Reduced sample sizes were present for: Rey figure (n = 9); VOSP cube analysis (n = 10); VOSP dot counting (n = 18); VOSP position discrimination (n = 11); PPT (n = 17); FAS (n = 17); Category fluency (n = 17); DASS (n = 14).

[^3]: Abbreviations: PCA Posterior cortical atrophy; HC2 Healthy controls group 2 (controls for imaging analysis).
